Latest News

ACASA-TAVI found NOAC monotherapy cut subclinical leaflet thrombosis nearly in half versus aspirin after TAVI, meeting safety noninferiority.

CMR GUIDE found ICD implantation did not significantly reduce sudden cardiac death or dangerous arrhythmia versus a loop recorder in LVEF 36-50%.

Phase 2b LUMINARA results showed the oral relaxin agonist AZD5462 improved echocardiographic measures of cardiac function in patients with chronic heart failure.

The Met-HeFT trial and a companion meta-analysis found metformin did not significantly improve cardiovascular outcomes in patients with HFrEF.

A roundup of the top cardiology news out of ESC Congress2026 on day 2, spanning primary prevention, novel therapies, and antibiotic stewardship.

New MILOS data show bempedoic acid-based therapy translated to meaningful reductions in predicted 10-year cardiovascular risk.

The REACT study found silent atherosclerosis in 57.1% of adults without known cardiovascular disease, a burden largely missed by the SCORE2 risk tool.

A longitudinal survey found PSVT disrupts patients' daily activities, sleep, and emotions between episodes.

Despite failing to display a clinically significant reduction in all-cause death or hospitalization for cardiovascular events, the trial did highlight evolocumab’s LDL-C-lowering capacity.

POET-II found tailored antibiotics cut treatment duration by a third in left-sided infective endocarditis without compromising safety, per ESC 2026 data.

PREMIUM found prasugrel monotherapy before primary PCI raised ischemic risk vs DAPT in STEMI despite less major bleeding, per ESC Congress 2026 data.

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

Milvexian added to standard antiplatelet therapy did not lower MACE or increase intracranial/fatal bleeding versus placebo after ACS.

The ENRICH-AF trial found edoxaban did not significantly reduce stroke or systemic embolism but increased major bleeding in patients with AF and prior intracranial hemorrhage.

STAREE findings show atorvastatin reduced major cardiovascular events by 30% in older adults without known cardiovascular disease, but disability-free survival was unchanged.

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

A roundup of the biggest cardiology news out of ESC Congress on day 1, spanning new guidelines, a phase 3 miss, and 2 practice-informing trial readouts.

An individual participant data meta-analysis found antihypertensive therapy reduced cardiovascular events only in patients with at least 80% medication adherence.

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

A new study has indicated the correlation between EHT and atrial myopathy, which in turn contributes to potential ischemic stroke incidence.

The updated ESC guidelines make sweeping changes to HF terminology, eliminating HFmrEF and recategorizing acute HF for patients with slower symptom development.

Both apixaban and rivaroxaban resulted in improved risk of stroke, systemic embolism, major bleeding, and cardiovascular death compared to no anticoagulation.

SURPASS-CVOT showed tirzepatide is non-inferior to dulaglutide for cardiovascular events in more than 13,000 adults with type 2 diabetes.